Cyclodextrin-based low melting mixtures as a solubilizing vehicle: Application to non-steroidal anti-inflammatory drugs

被引:11
作者
El Masri, Sarah [1 ,2 ]
Ruellan, Steven [1 ]
Zakhour, Maha [2 ]
Auezova, Lizette [2 ]
Fourmentin, Sophie [1 ]
机构
[1] Univ Littoral Cote dOpale, Unite Chim Environm & Interact Vivant UCEIV, EA 4492 SFR Condorcet FR CNRS 3417, Dunkerque, France
[2] Lebanese Univ, Fac Sci, Doctoral Sch Sci & Technol, Bioact Mol Res Lab, Fanar, Lebanon
关键词
Cyclodextrins; Deep eutectic solvents; Low melting mixtures; Non-steroidal anti-inflammatory drugs; Solubility; DEEP EUTECTIC SOLVENTS; CLINICAL PHARMACOKINETICS; BETA-CYCLODEXTRIN; INCLUSION COMPLEXES; FLURBIPROFEN; NAPROXEN; NSAIDS; WATER; SYSTEM; KETOPROFEN;
D O I
10.1016/j.molliq.2022.118827
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
Poor water solubility represents a serious issue for drug formulation and delivery. Cyclodextrins (CDs) and cosolvents are valuable approaches to overcome this issue. Currently, there is a growing interest in deep eutectic solvents (DESs) with high solubilizing ability and low toxicity. Low melting mixtures (LMMs) based on CDs have recently emerged, combining the solubilizing properties of solvents and drug carriers. In this study, we evaluated the solubility of ketoprofen, flurbiprofen and naproxen in two mixtures based on levulinic acid (Lev). The effect of water on the solubilizing potential and viscosity of these mixtures was assessed. Also, the stability of the studied drugs was monitored up to one year. The LMM based on randomly methylated-b-cyclodextrin (RAMEB) showed the highest solubilizing potential (up to 5012-fold the aqueous solubility) compared to the DES based on choline chloride. Formation of RAMEB/drug inclusion complex in the LMM was evidenced by nuclear magnetic resonance spectroscopy (NMR). Adding water (10 wt%) sharply reduced the viscosity of both mixtures while maintaining their high solubilizing ability. Moreover, the studied drugs were stable up to 90% in both mixtures after a year at 25 degrees C. Such low-viscous mixtures endowed with high solubilizing and stabilizing properties have great potential for pharmaceutical applications. (c) 2022 Elsevier B.V. All rights reserved.
引用
收藏
页数:9
相关论文
共 54 条
[1]   Novel solvent properties of choline chloride/urea mixtures [J].
Abbott, AP ;
Capper, G ;
Davies, DL ;
Rasheed, RK ;
Tambyrajah, V .
CHEMICAL COMMUNICATIONS, 2003, (01) :70-71
[2]  
Alsarra IA, 2010, INT J MED SCI, V7, P232
[3]   Liquisolid technology: What it can do for NSAIDs delivery? [J].
Azharshekoufeh B, Leila ;
Shokri, Javad ;
Adibkia, Khosro ;
Javadzadeh, Yousef .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2015, 136 :185-191
[4]   Encapsulation of NSAIDs for inflammation management: Overview, progress, challenges and prospects [J].
Badri, Waisudin ;
Miladi, Karim ;
Nazari, Qand Agha ;
Greige-Gerges, Helene ;
Fessi, Hatem ;
Elaissari, Abdelhamid .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 515 (1-2) :757-773
[5]   Cyclodextrins as pharmaccutical solubilizers [J].
Brewster, Marcus E. ;
Loftsson, Thorsteinn .
ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (07) :645-666
[6]  
BROOKS PM, 1991, NEW ENGL J MED, V324, P1716
[7]   Drug delivery system based on cyclodextrin-naproxen inclusion complex incorporated in electrospun polycaprolactone nanofibers [J].
Canbolat, M. Fatih ;
Celebioglu, Asli ;
Uyar, Tamer .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2014, 115 :15-21
[8]   Dendrimers as potential drug carriers. Part I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers [J].
Cheng, YY ;
Xu, TW .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2005, 40 (11) :1188-1192
[9]   Determination of stability constant values of flurbiprofen-cyclodextrin complexes using different techniques [J].
Cirri, M ;
Maestrelli, F ;
Orlandini, S ;
Furlanetto, S ;
Pinzauti, S ;
Mura, P .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2005, 37 (05) :995-1002
[10]   Development of fast-dissolving tablets of flurbiprofen-cyclodextrin complexes [J].
Cirri, M ;
Rangoni, C ;
Maestrelli, F ;
Corti, G ;
Mura, P .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2005, 31 (07) :697-707